High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.


Journal

Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041

Informations de publication

Date de publication:
03 2022
Historique:
received: 09 12 2021
accepted: 29 01 2022
revised: 28 01 2022
pubmed: 2 2 2022
medline: 5 4 2022
entrez: 1 2 2022
Statut: ppublish

Résumé

Tumors of the central nervous system (CNS) often display a wide morphologic spectrum that has, until recently, been the sole basis for tumor classification. The introduction of the integrated histomolecular diagnostic approach in CNS tumors has facilitated a classification system that is increasingly data-driven and with improved alignment to clinical outcome. Here, we report a previously uncharacterized glioma type (n = 31) using unsupervised clustering analysis of DNA methylation array data from approximately 14,000 CNS tumor samples. Histologic examination revealed circumscribed growth and morphologic similarities to pleomorphic xanthoastrocytoma (PXA), astroblastoma, ependymoma, polymorphous neuroepithelial tumor of the young (PLNTY), and IDH-wildtype glioblastoma (GBM). Median age (46.5 years) was significantly older than other circumscribed gliomas and younger than GBM. Dimensionality reduction with uniform manifold approximation and projection (UMAP) and hierarchical clustering confirmed a methylation signature distinct from known tumor types and methylation classes. DNA sequencing revealed recurrent mutations in TP53 (57%), RB1 (26%), NF1 (26%), and NF2 (14%). BRAF V600E mutations were detected in 3/27 sequenced cases (12%). Copy number analysis showed increased whole chromosome aneuploidy with recurrent loss of chromosome 13 (28/31 cases, 90%). CDKN2A/B deletion (2/31, 6%) and MGMT promoter methylation (1/31, 3%) were notably rare events. Most tumors showed features of a high-grade glioma, yet survival data showed significantly better overall survival compared to GBM (p < 0.0001). In summary, we describe a previously uncharacterized glioma of adults identified by a distinct DNA methylation signature and recurrent loss of chromosome 13.

Identifiants

pubmed: 35103816
doi: 10.1007/s00401-022-02404-9
pii: 10.1007/s00401-022-02404-9
pmc: PMC9844519
mid: NIHMS1860408
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

403-414

Subventions

Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States

Informations de copyright

© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Références

Acta Neuropathol. 2018 Aug;136(2):181-210
pubmed: 29967940
Cell. 2016 Feb 25;164(5):1060-1072
pubmed: 26919435
Acta Neuropathol. 2012 Oct;124(4):547-60
pubmed: 22810491
Acta Neuropathol. 2018 Aug;136(2):273-291
pubmed: 29564591
Acta Neuropathol. 2014 Aug;128(2):279-89
pubmed: 24337497
Neuro Oncol. 2022 Apr 1;24(4):571-581
pubmed: 34555175
J Mol Diagn. 2016 May;18(3):350-361
pubmed: 26927331
Bioinformatics. 2018 Dec 1;34(23):3983-3989
pubmed: 29931280
Neuropathol Appl Neurobiol. 2020 Feb;46(2):190-193
pubmed: 31863478
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Acta Neuropathol. 2019 Jan;137(1):175-177
pubmed: 30446821
J Neurooncol. 2021 May;153(1):109-120
pubmed: 33905054
Nat Commun. 2021 Jan 21;12(1):498
pubmed: 33479225
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Lancet Oncol. 2022 Jan;23(1):3-4
pubmed: 34838157
Nat Genet. 2021 Dec;53(12):1664-1672
pubmed: 34857952
Lancet Oncol. 2022 Jan;23(1):53-64
pubmed: 34838156
Acta Neuropathol Commun. 2019 Mar 15;7(1):42
pubmed: 30876455
Acta Neuropathol Commun. 2020 Jul 8;8(1):101
pubmed: 32641156
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Oncologist. 2019 Dec;24(12):1584-1592
pubmed: 31346129
Acta Neuropathol. 2022 Jan;143(1):109-113
pubmed: 34825267
Nucleic Acids Res. 2017 Feb 28;45(4):e22
pubmed: 27924034
Neurooncol Adv. 2020 Oct 24;3(1):vdaa145
pubmed: 33543142

Auteurs

Drew Pratt (D)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA. prattdw@nih.gov.

Zied Abdullaev (Z)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA.

Antonios Papanicolau-Sengos (A)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA.

Courtney Ketchum (C)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA.

Pavalan Panneer Selvam (P)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA.

Hye-Jung Chung (HJ)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA.

Ina Lee (I)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA.

Mark Raffeld (M)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA.

Mark R Gilbert (MR)

Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Terri S Armstrong (TS)

Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Peter Pytel (P)

Department of Pathology, University of Chicago Medicine, Chicago, IL, USA.

Ewa Borys (E)

Department of Pathology, Loyola University Medical Center, Maywood, IL, USA.

Joshua M Klonoski (JM)

Department of Pathology and ARUP Laboratories, University of Utah Health Sciences Center, Salt Lake City, USA.

Matthew McCord (M)

Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Craig Horbinski (C)

Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Daniel Brat (D)

Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Arie Perry (A)

Department of Pathology, University of California, San Francisco, CA, USA.

David Solomon (D)

Department of Pathology, University of California, San Francisco, CA, USA.

Charles Eberhart (C)

Department of Neuropathology and Ophthalmic Pathology, Johns Hopkins University, Baltimore, MD, USA.

Caterina Giannini (C)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Martha Quezado (M)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA.

Kenneth Aldape (K)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20814, USA. kenneth.aldape@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH